Tbg Diagnostics Share Price and Company Fundamentals



Price
$0.27
Change
0.270 (0.000%)
52 week
0.27 - 0.27

Last traded: 03/17/2020

TBG Diagnostics Limited, a molecular diagnostics company, develops, manufactures, and markets molecular diagnostics kits, instruments, and services in Taiwan and China. It provides ExProbe HLA and HPA kits for human leukocyte antigen (HLA) and human platelet antigens (HPA) allele genotyping, which uses real time polymerase chain reaction (PCR) techniques with sequence specific primers and probes; Morgan SSP HLA kits for determining HLA alleles using PCR techniques with sequence specific primers; HLAssure SBT HLA Kits for transplantation donor selection; and AccuType SBT analysis software to analyze sequences from all ab1 based files. The company also offers Morgan SSPal HLA Typing Analysis Software, a gel result interpretation software; HLA typing services that offer low to high resolution using PCR fragment analysis (SSP) and DNA sequencing (SBT); QPCR Q6000, a six-channel real time PCR instrument; QzNGS NGS that provides high resolution HLA genotyping; and COVID-19 testing kits. It serves clinical labs, blood centers, and bone marrow registry labs. The company was formerly known as Progen Pharmaceuticals Limited and changed its name to TBG Diagnostics Limited in December 2015. TBG Diagnostics Limited was incorporated in 1989 is based in Greenslopes, Australia.

Key Metrics

PE ratio

-

PB ratio

10.00

Dividend yield

Beta

-12.52

Market cap

$58.75M

Enterprise value

$59.28M

Company profile

Primary activitiesA global molecular diagnostics company dedicated to the development, manufacture and marketing of molecular diagnostics kits, instruments and services.
Industry / SectorDiagnostics & Research / Healthcare
Websitehttp://www.tbgbio.com
Mailing address138 Juliette Street Unit 6 Greenslopes QLD 4120 Australia
Phone / Fax61 7 3088 7926 / 61 7 3394 4394
Share registryCOMPUTERSHARE INVESTOR SERVICES PTY LIMITED

Dividends

Tbg Diagnostics does not pay dividends.

Company Executives

As of May 2021, following are the company executives and directors listed on Tbg Diagnostics.

NameTitleAgeTotal Pay
Mr. Indrajit Solomon ArulampalamExec. Chairman80k
Ms. Generosa HiponaCFO & GM of Fin.170.06k
Mr. Justyn Peter Stedwell B.Com., B.ComCompany Sec.49.4k
Mr. Willy M. HsuChief Operating Officer
Dr. Michael ChenChief Scientific Officer
Dr. Edward HammondHead of Biology
Dr. Paul HandleyHead of Chemistry
Dr. Tomislav KaroliHead of Process Chemistry
Mr. Ifan ChiuPres of TBG (Xiamen) Inc

Profitability and management effectiveness

Profit margin

-77.05%

Operating margin

-74.24%

Return on assets

-14.28%

Return on equity

-38.05%

Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.

The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.

Valuation and Trading Info

The market capitalization of Tbg Diagnostics is 58.75M and its enterprise value is 59.28M. The enterprise value to revenue ratio of TDL is 12.87.

Companies similar to Tbg Diagnostics (TDL)

Tbg Diagnostics (ASX:TDL) Frequently Asked Questions

1. What is Tbg Diagnostics's Stock Symbol?

Tbg Diagnostics trades on ASX under the ticker symbol "TDL".

2. What is Tbg Diagnostics's stock price today?

One share of TDL stock can currently be purchased for approximately $0.27.

3. How can I contact Tbg Diagnostics?

Tbg Diagnostics's mailing address is 138 Juliette Street Unit 6 Greenslopes QLD 4120 Australia. The company can be reached via phone at 61 7 3088 7926.

4. What is Tbg Diagnostics's official website?

The official website of Tbg Diagnostics is http://www.tbgbio.com.

5. Which share registry manages Tbg Diagnostics's stock?

Tbg Diagnostics's stock is managed by COMPUTERSHARE INVESTOR SERVICES PTY LIMITED.